CHIP Testing vs Standard Cardiovascular Risk Assessment
How clonal hematopoiesis (CHIP) testing compares with lipids, Lp(a), blood pressure, risk calculators, and a calcium score. CH complements standard assessment, it does not replace it.
Medically reviewed by Rhonda Collins, FNP-C | Mito Health on August 27, 2026.
Standard cardiovascular risk assessment and clonal hematopoiesis (CH, often called CHIP) testing answer different questions, so the honest framing is complementary, not competitive. Standard assessment measures the drivers and current burden of atherosclerosis: cholesterol and ApoB, lipoprotein(a), blood pressure, a risk calculator, and often a coronary artery calcium score. CH testing adds an inflammatory, aging-related blood signal that lipids do not capture. CH is not a diagnosis and not a guideline-endorsed population screening test, and its cardiovascular associations come from observational studies, so they show association rather than causation. It complements standard risk assessment. It does not replace it.
What is standard cardiovascular risk assessment, and what does it measure?
Standard assessment is the well-validated foundation of preventive cardiology. It combines several measurements that each capture a different piece of atherosclerotic risk:
- Lipids and ApoB. A lipid panel measures LDL cholesterol, HDL cholesterol, and triglycerides. Apolipoprotein B (ApoB) counts the atherogenic particles that actually deposit cholesterol in the artery wall, which is why many clinicians treat it as a more precise measure of that burden.
- Lipoprotein(a). Lp(a) is a largely inherited, independent risk factor that a standard lipid panel does not report unless it is ordered specifically.
- Blood pressure. A core, modifiable driver of both heart attack and stroke.
- Risk calculators. Tools such as the pooled cohort equations combine age, sex, blood pressure, cholesterol, smoking, and diabetes into an estimated 10-year risk to guide prevention decisions.
- Coronary artery calcium (CAC) score. A CT-based score that quantifies existing calcified plaque, giving a direct look at accumulated disease rather than a projection.
Together these measure the causes of plaque and, in the case of a calcium score, the plaque that is already there.
What does clonal hematopoiesis testing add?
CH testing looks at something the panel above does not measure at all: an inflammatory, aging-related signal in the blood-forming system. Clonal hematopoiesis occurs when a blood stem cell acquires a mutation that lets it expand into a larger population of mutated blood cells. This is an inflammatory process, it becomes more common with each decade past 40, and the same clones linked to blood cancers are also linked to cardiovascular risk (Jaiswal S and Ebert BL, Science, 2019;366:eaan4673).
In cohort studies, CH carriers had a roughly 1.9-fold higher risk of coronary heart disease (HR = 1.9; 95% CI 1.4 to 2.7), rising to about 12-fold in the subset carrying the JAK2 V617F mutation specifically (HR = 12.0; 95% CI 3.8 to 38.4), and case-control studies put early-onset heart attack at roughly 4-fold (OR = 4.0; 95% CI 2.4 to 6.7) (Jaiswal S et al., New England Journal of Medicine, 2017;377:111). Ischemic stroke was reported at roughly 2.6-fold (HR = 2.6; 95% CI 1.4 to 4.8; Jaiswal S et al., New England Journal of Medicine, 2014;371:2488), and blood cancer at roughly 12.9-fold (HR = 12.9; 95% CI 5.8 to 28.7; Genovese G et al., New England Journal of Medicine, 2014;371:2477). These are associations from observational studies, not proof of causation, and not individual predictions.
The practical point is that this signal is independent of lipids. It can be present in someone whose cholesterol and blood pressure look reassuring, which helps explain part of why roughly 1 in 4 heart attack patients (Paul G et al., Global Heart, 2023;18(1)) and about 1 in 5 stroke patients (Beharry J et al., European Stroke Journal, 2025) have no known traditional risk factors at the time of their event. CardioHemeRISK is one such test: a prescription-only blood test that examines CH mutations across 15 genes and returns a risk-oriented score.
What does each approach capture?
Approach | What it measures | What it does not capture |
|---|---|---|
Lipid panel and ApoB | Cholesterol and the atherogenic particle count that drives plaque | Inflammatory or aging signals; existing plaque burden |
Lipoprotein(a) | An inherited, independent lipid-related risk factor | Acquired, age-related risk; modifiable drivers |
Blood pressure | A core modifiable driver of heart attack and stroke | Lipid particle burden; blood-cell inflammatory signals |
Risk calculator (e.g. pooled cohort equations) | An estimated 10-year risk from established factors | Non-traditional signals such as clonal hematopoiesis |
Coronary artery calcium (CAC) score | Calcified plaque that has already accumulated | Why plaque is forming; future inflammatory risk |
Clonal hematopoiesis (CardioHemeRISK) | An inflammatory, aging-related blood signal associated with risk | Lipids, blood pressure, or existing plaque; it is not diagnostic |
Each approach captures a different piece of cardiovascular risk. Clonal hematopoiesis associations are observational and show association, not causation. Sources: Jaiswal S et al., New England Journal of Medicine, 2017;377:111; Genovese G et al., New England Journal of Medicine, 2014;371:2477.
Does CH testing replace lipids, a risk calculator, or a calcium score?
No. Standard cardiovascular risk assessment is the validated backbone of prevention, and CH testing does not change that. CH is a newer, non-traditional signal that is not part of any guideline-endorsed screening pathway, and detecting it does not by itself prove that acting on it changes outcomes. The value of a CH result comes from reading it next to lipids, ApoB, Lp(a), blood pressure, and, when appropriate, a calcium score, so an additional inflammatory signal is weighed alongside the drivers and the existing plaque burden it does not measure. If CH is elevated, the highest-yield response is still to tighten the modifiable risk factors that standard assessment identifies.
Who might consider adding CH testing?
CH becomes more common with age and is more frequently found in specific groups: healthy adults roughly 40 to 80, cancer survivors treated with chemotherapy or radiation, and people with a history of atherosclerotic disease or its risk factors such as family history, hypertension, or high cholesterol (Jakubek YA et al., Translational Research, 2023;255:171). Someone with a strong risk picture but unremarkable lipids, or someone building a comprehensive longevity-oriented workup, may raise CH testing with their doctor. It is an individualized decision, not a population mandate.
How Mito brings both together
The most useful place for a CH signal is inside a complete cardiovascular picture, and that is the Mito-distinctive angle. You can order and trend the standard markers, ApoB, Lp(a), LDL cholesterol, and inflammation markers like hs-CRP, then read a CH result alongside them rather than in isolation.
CardioHemeRISK is prescription-only, costs $899.64 ($642.60 for Mito members), and is HSA and FSA eligible. Ordering runs through a telehealth partner who reviews and orders the test if appropriate, with mobile phlebotomy and results delivered back through the partner. Once results are in, you can ask follow-up questions through Mito Concierge and book a 1:1 consultation to turn the full set of numbers into a plan.
See what a CH blood test covers, or take the quiz to build your cardiovascular workup first.
CHIP testing vs standard cardiovascular risk assessment questions
Does CHIP testing replace a lipid panel or calcium score? No. It adds an inflammatory, aging-related signal that lipids and a calcium score do not capture. Standard assessment stays the foundation.
Is CHIP testing better than standard cardiovascular risk assessment? Neither is better. They measure different things. Standard assessment measures the drivers and burden of plaque, and CH adds a separate, non-traditional signal that is interpreted alongside them.
Can I have elevated CH with normal cholesterol? Yes. CH is independent of lipids, so it can be present when cholesterol and blood pressure look reassuring.
Is CHIP testing part of standard screening guidelines? No. CH is a promising, measurable, age-associated signal, but it is not a guideline-endorsed population screening test, and its cardiovascular associations are observational.
What should I do first? Start with standard cardiovascular risk assessment. If you and your doctor want to explore a non-traditional signal beyond lipids and blood pressure, CH testing can be one addition to that conversation.
Related reading
- Clonal Hematopoiesis and Heart Disease: What the Link Means
- What Is Clonal Hematopoiesis (CHIP)?
- Silent Heart Attack: Risk Factors With No Warning Signs
- Apolipoprotein B (ApoB): What Your Level Means
- Lipoprotein(a): An Inherited Cardiovascular Risk Factor
Medical disclaimer
This article is for informational purposes only and does not constitute medical advice. It does not diagnose heart disease or clonal hematopoiesis, and it does not replace standard cardiovascular risk assessment or medical care. CardioHemeRISK is a prescription-only laboratory test, not a diagnosis, and the risk associations described here come from observational studies, so they show association rather than causation. A qualified clinician should interpret any result in the context of your symptoms, history, examination, and other testing.
